Drug Type Synthetic peptide |
Synonyms MK 0616, MK-0616, MK0616 |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC82H110ClFN14O15 |
InChIKeyCLOLWQCFULXMAR-DULRACIBSA-N |
CAS Registry2407527-16-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Arteriosclerosis | Phase 3 | US | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | CN | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | JP | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | AR | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | AU | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | BR | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | CA | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | CL | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | CO | 09 Oct 2023 | |
Arteriosclerosis | Phase 3 | DK | 09 Oct 2023 |
Phase 2 | 381 | (MK-0616 6 mg) | zoxtpovtqo(hhaunjpptf) = fzxtcqniny bwlafyoqrm (mgniahifzv, rnldwoxyfi - htvffpaqgt) View more | - | 06 Dec 2023 | ||
(MK-0616 12 mg) | zoxtpovtqo(hhaunjpptf) = ginvycxdac bwlafyoqrm (mgniahifzv, cbfkyougql - xeiwqsjxbe) View more | ||||||
Phase 2 | 381 | pbioldmchd(wytuqvwwpv) = gybzzssmtv iatroyzggr (glmfocjbvm ) View more | Positive | 06 Mar 2023 | |||
pbioldmchd(wytuqvwwpv) = lmqdyrukoe iatroyzggr (glmfocjbvm ) View more | |||||||
Phase 2 | 381 | mfroufvlvk(cchrbqqrsr) = cyxxyafwjg nkjbhgkynd (ubiorfcski ) | Positive | 16 Feb 2023 | |||
mfroufvlvk(cchrbqqrsr) = iakbkdzvlm nkjbhgkynd (ubiorfcski ) |